MedPath

A multicenter, prospective cohort study of pediatric pulmonary fever Qing granules for community-acquired pneumonia in children based on a realistic medical setting

Phase 4
Recruiting
Conditions
community-acquired pneumonia in children
Registration Number
ITMCTR2200006542
Lead Sponsor
Beijing Children's Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

(1) Community-acquired pneumonia in children diagnosed as a Western medicine disease;

(2) TCM syndrome differentiation is heat evil pulmonary closure syndrome;

(3) Age 1-14 years (=14 years);

(4) Course of disease =5 days;

(5) The informed consent meets the requirements. Children aged =8 years shall sign the informed consent with their guardian

Exclusion Criteria

(1) Patients with central cyanosis, severe respiratory distress, food refusal or dehydration signs, and disturbance of consciousness (lethargy, coma, convulsion);

(2) Patients with nausea, vomiting, diarrhea and other gastrointestinal reactions;

(3) Complicated with other respiratory infectious diseases, immune system diseases, malignant tumors;

(4) Patients with liver and kidney dysfunction and severe hematopoietic system diseases;

(5) Allergic to the drug in this study or the investigator considers it inappropriate to enter this study

Study & Design

Study Type
Observational study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Clinical recovery time;
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath